Consensus LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
11.95 ^USD	+10.44%		+23.20%	+44.15%

04-23	BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	MT
03-12	Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	MT

Evolution of the average Target Price on LifeMD, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1bba49d9cf284139364.8obKruN-vBTmB0s-ozkO8PxOTA9R6rhYObiR5PL50k4.peWlwtIb1CSeSSxmxG9lqK40K2EYq4FuU43Cs4vIlwuAwfPZlgn3cLFYCg~22a29449e2e62654ffa95501adc83511

Analyst Recommendations on LifeMD, Inc.

BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	04-23	MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	03-12	MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	03-12	MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	03-12	MT
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	01-11	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	11-14	MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	11-09	MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	11-09	MT
Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	02/10/23	MT
Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	21/07/23	MT
B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	10/07/23	MT
HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	03/07/23	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23/03/23	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23/03/23	MT
B. Riley Lowers LifeMD's Price Target to $8 from $16, Notes Slower-than-Anticipated Start in Q1 Impacted by Technology Upgrades, Integrations; Keeps Buy Rating	16/05/22	MT
BTIG Adjusts LifeMD's Price Target to $15 From $30, Reiterates Buy Rating	11/11/21	MT
LIFEMD : BTIG Research Adjusts LifeMD Price Target to $30 From $35, Maintains Buy Rating	13/08/21	MT
LIFEMD : BTIG Adjusts LifeMD's Price Target to $35 From $40, Reiterates Buy Rating	19/07/21	MT
CONVERSION LABS : B. Riley Starts Conversion Labs at Buy With $35 Price Target	05/02/21	MT
CONVERSION LABS : BTIG Starts Conversion Labs at Buy With $15 Price Target	07/01/21	MT